Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response to novel therapies, hence justifying the mass of attention MRD testing is receiving in multiple myeloma (MM). From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, chairs an insightful discussion with Jens Lohr, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, and Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, on the promising prospects of emerging, highly sensitive techniques for MRD testing. This podcast covers the enthralling discussion between the trio as they also tackle the question of how far away MRD testing is from prime time and routine clinical use in MM.

The post MRD testing in multiple myeloma: new technology with promising clinical applications appeared first on VJHemOnc.